Pivot Pharmaceuticals Inc., a development stage pharmaceutical and nutraceutical company, engages in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using drug delivery platform technologies in Canada. The company offers its products for cancer supportive care, pain and inflammation, women's sexual dysfunction, dermatology, and eye diseases. It also focuses on the research, development, and commercialization of cannabinoid based nutraceuticals. The company was formerly known as Neurokine Pharmaceuticals Inc. and changed its name to Pivot Pharmaceuticals Inc. in April 2015. Pivot Pharmaceuticals Inc. was founded in 2002 and is based in Vancouver, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone604-805-7783
Debt
Current Ratio0.15
Quick Ratio0.15
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / BookN/A
Profitability
Net Income$-120,000.00
Net MarginsN/A
Return on Assets-85.25%
Miscellaneous
EmployeesN/A
OptionableNot Optionable
Pivot Pharmaceuticals (OTCMKTS:PVOTF) Frequently Asked Questions
What is Pivot Pharmaceuticals' stock symbol?
Pivot Pharmaceuticals trades on the OTCMKTS under the ticker symbol "PVOTF."
How were Pivot Pharmaceuticals' earnings last quarter?
When is Pivot Pharmaceuticals' next earnings date?
Has Pivot Pharmaceuticals been receiving favorable news coverage?
News articles about PVOTF stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pivot Pharmaceuticals earned a news sentiment score of -1.6 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Pivot Pharmaceuticals' key competitors?
Some companies that are related to Pivot Pharmaceuticals include Advanced Accelerator Application (AAAP), Aerpio Pharmaceuticals (ARPO), AgeX Therapeutics (AGE), American Oriental Bioengineering (AOBI), Anthera Pharmaceuticals (ANTH), Aralez Pharmaceuticals (ARLZ), Argos Therapeutics (ARGS), ARMO Biosciences (ARMO), Biostar Pharmaceuticals (BSPM), Bohai Pharmaceuticals Group (BOPH), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO) and Egalet (EGLT).
Who are Pivot Pharmaceuticals' key executives?
Pivot Pharmaceuticals' management team includes the folowing people:
- Dr. Patrick Charles Frankham, CEO, Pres & Director (Age 48)
- Ms. Moira Ong, Chief Financial Officer (Age 44)
- Dr. Ahmad Doroudian, Advisor (Age 59)
- Dr. Joseph Borovsky, Chairman, Exec. VP of Product Devel. & Member of Scientific Advisory Board
- Dr. Wolfgang Renz M.D., Ph.D., Chief Medical Officer & Director (Age 50)
How do I buy shares of Pivot Pharmaceuticals?
Shares of PVOTF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pivot Pharmaceuticals' stock price today?
One share of PVOTF stock can currently be purchased for approximately $0.1792.
What is Pivot Pharmaceuticals' official website?
How can I contact Pivot Pharmaceuticals?
Pivot Pharmaceuticals' mailing address is 1275 WEST 6TH AVENUE, VANCOUVER A1, V6H 1A6. The company can be reached via phone at 604-805-7783.
MarketBeat Community Rating for Pivot Pharmaceuticals (OTCMKTS PVOTF)
MarketBeat's community ratings are surveys of what our community members think about Pivot Pharmaceuticals and other stocks. Vote "Outperform" if you believe PVOTF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PVOTF will underperform the S&P 500 over the long term. You may vote once every thirty days.
